Latanoprost Unimed Pharma (Latanoprost)

Latanoprost mimics prostaglandin F2α and binds to FP receptors in the eye’s ciliary body. This binding enhances the uveoscleral outflow pathway, allowing aqueous humor to drain more efficiently and thereby reducing intra‑ocular pressure.

The dosing regimen for latanoprost is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and frequency should follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong IOP‑lowering efficacy. Compared with beta‑blockers such as timolol, latanoprost often provides greater pressure reduction with a different side‑effect profile, making it a common first‑line option.

Latanoprost should be stored at room temperature, below 25 °C, in its original container. Protect the bottle from light and moisture, and avoid freezing. Do not shake the solution before use; gently invert if needed.

The medication is applied as a single drop into the affected eye(s) once daily, preferably in the evening. The patient should wash hands, avoid touching the tip of the bottle to the eye or any surface, and wait a few minutes before applying other eye drops.

Serious but rare risks include a paradoxical increase in intra‑ocular pressure, uveitis, corneal edema, and severe allergic reactions such as contact dermatitis or systemic hypersensitivity. Patients should seek immediate medical attention if they experience significant eye pain, redness, or vision changes.

Latanoprost should not be used by individuals with active ocular inflammation (e.g., uveitis), known hypersensitivity to latanoprost or any component of the formulation, or those who are currently using other prostaglandin analog eye drops. Caution is also advised in patients with a history of herpetic eye disease.